The association between the epsilon-4 type allele of apolipoprotein E (APOE ε4) and depression was investigated in 323 AD patients. Patients were divided into two groups based on the presence (n=61) or absence (n=262) of depression as assessed by the DSM-based Diagnostic Interview Schedule. Both subgroups were demographically comparable with regard to age, education, gender, and severity of cognitive impairment. Analysis of the frequency of APOE ε4 alleles between the groups revealed a significantly higher prevalence rate of the APOE ε4 genotype in the depressed group (72% of depressed AD patients carried at least one copy of the ε4 allele) compared to the non-depressed AD patients (58%). This effect was primarily accounted for by women. Specifically, an interaction was revealed wherein women who possessed the APOE ε4 allele were almost 4 times more likely to be depressed in comparison to those who did not carry the allele, and APOE ε4 status did not predict depression among men in our sample. These results are consistent with recent suggestions that the APOE ε4 genotype may be over-represented among women with AD and depression and highlight a need for additional research investigating the links between APOE genotype, mood, and gender.Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive neuropsychological, functional, and behavioral decline. Currently, there are 4.5 million people with AD in the United States and the prevalence is expected to increase to 11 -16 million by 2050 (Alzheimer's Association, 2004. Psychiatric disturbance is frequently seen in AD and, although prevalence rates vary considerably across studies (e.g., 1 -90%), average rates of coexisting AD and depression appear to hover around 20 to 40% (Wragg & Jeste, 1989;Cummings, Ross, Absher, Gornbein & Hadjiaghai, 1995;Tractenberg, Weiner, Patterson, Teri, & Thal, 2003;Green et al., 2003). Lyketsos and Olin (2002) reported that behavioral disturbances among AD patients are 3 to 4 times higher than that seen in normal aging.Adverse consequences of depression in patients with AD are numerous, including greater impairment in activities of daily living (Lyketsos et al., 1997b), poorer quality of life (GonzalesSalvador et al., 2000), earlier institutionalization (Magni, Bionetti, Bianchetti, & Trabucchi, 1996), greater caregiver depression and level of burden (Gonzales-Salvador et al., 1999) (Stern et al., 1997), and higher mortality rates (Ganguli, Hodge, & Mulsant, 2002;Hoch et al., 1993). In addition, neuropsychiatric symptoms significantly increase direct annual costs of care among AD patients, even after adjusting for the severity of cognitive impairment and other medical comorbidities (Murman et al, 2002).Neuropathologically, depressive symptoms appear to be associated with a selective loss of noradrenergic and serotonergic nuclei in the brainstem (Zubenko, 2000) and these losses may be related to genetic risk factors for AD (Craig, Hart, McIlroy, & Passmore, 2005). Although it is now clear ...